Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
How has V. Gounant's publication output changed over time?
ScholarIQpublication output · 2009–2022
Output grew0% over the shown period — from 1 works in 2009 to 1 in 2022.
1
1
1
1
4
1
1
1
20092012201520172019202020212022
What are the most-cited papers on V. Gounant?
ScholarIQmost cited works
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
J. Mazieres, Alexander Drilon, Amélie Lusque, Laurent Mhanna, Alexis B. Cortot, Laura Mezquita, Alesha A. Thai, Céline Mascaux, S. Couraud, Rémi Veillon, Michel M. van den Heuvel, Joel W. Neal, Nir Peled, Martin Früh, Terry L. Ng, V. Gounant, Sanjay Popat, Joachim Diebold, Joshua K. Sabari, Viola W. Zhu, Sacha I. Rothschild, Paolo Bironzo, Alex Martínez‐Martí, Alessandra Curioni‐Fontecedro, Rafael Rosell, Mickaël Lattuca-Truc, Marcel Wiesweg, Benjamin Besse, Benjamin Solomon, Fabrice Barlési, Robert D. Schouten, Heather A. Wakelee, D. Ross Camidge, Gérard Zalcman, Silvia Novello, Sai‐Hong Ignatius Ou, Julie Milia, Oliver Gautschi
Annals of Oncology. 20191,375 CitationsOPEN ACCESS
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gérard Zalcman, Julien Mazières, J. Margery, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Olivier Molinier, R. Corre, I. Monnet, V. Gounant, F. Rivière, Henri Janicot, Radj Gervais, Chrystèle Locher, B. Milleron, Quan Le Tran, Marie-Paule Lebitasy, Franck Morin, Christian Créveuil, Jean‐Jacques Parienti, Arnaud Scherpereel
The Lancet. 2015975 Citations
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Myriam Delaunay, J. Cadranel, Amélie Lusque, Nicolás Meyer, V. Gounant, Denis Moro‐Sibilot, Jean‐Marie Michot, Judith Raimbourg, Nicolas Girard, Florian Guisier, David Planchard, Anne-Cécile Métivier, Pascale Tomasini, Éric Dansin, M. Pérol, M. Campana, Oliver Gautschi, Martin Früh, Jean-David Fumet, Clarisse Audigier-Valette, S. Couraud, Stéphane Dalle, M.‐T. Leccia, M. Jaffro, S. Collot, Grégoire Prévôt, Julie Milia, Julien Mazières
S4210207896. 2017424 CitationsOPEN ACCESS
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette, Denis Moro‐Sibilot, Lionel Uwer, J. Hureaux, Florian Guisier, D. Carmier, J. Madelaine, Josiane Otto, V. Gounant, P. Merle, Pierre Mourlanette, Olivier Molinier, Aldo Renault, Audrey Rabeau, Martine Antoine, Marc G. Denis, Sébastien Bommart, Alexandra Langlais, Franck Morin, Pierre-Jean Souquet
Journal of Thoracic Oncology. 2019182 CitationsOPEN ACCESS
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Sandra Assoun, Nathalie Théou–Anton, Marina Nguenang, Aurélie Cazes, Claire Danel, Baptiste Abbar, Johan Pluvy, V. Gounant, Antoine Khalil, Céline Namour, Solenn Brosseau, Gérard Zalcman
Lung Cancer. 2019173 CitationsOPEN ACCESS
Related on ScholarIQ
Lyon 1 Université
Institution
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry
Paper
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Paper
Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients
Paper
A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial
Paper
Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer
Paper